Picture loading failed.

Anti-ACVR2B therapeutic antibody (Pre-made Bimagrumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-069-1mg 1mg 3090
GMP-Bios-ab-069-10mg 10mg 21890
GMP-Bios-ab-069-100mg 100mg 148000
GMP-Bios-ab-069-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-ACVR2B therapeutic antibody (Pre-made Bimagrumab biosimilar,Whole mAb)
INN Name Bimagrumab
TargetACVR2B
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI Structure5nhr:HL:AB
99% SI Structure5nhw:HL/5nh3:HL:IM/5ngv:HL
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesMorphoSys;Novartis
Conditions Approvedna
Conditions ActiveCachexia;Muscular atrophy;Type 2 diabetes mellitus
Conditions DiscontinuedInclusion body myositis
Development TechMorphoSys HuCAL Phage Display